{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:59:22Z","timestamp":1790675962002,"version":"4.1.0"},"reference-count":28,"publisher":"Society of Nuclear Medicine","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.2967\/jnumed.121.262543","type":"journal-article","created":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T21:10:21Z","timestamp":1626469821000},"page":"1447-1456","source":"Crossref","is-referenced-by-count":39,"title":["Safety of PSMA-Targeted Molecular Radioligand Therapy with <sup>177<\/sup>Lu-PSMA-617: Results from the Prospective Multicenter Phase 2 Trial RESIST-PC (NCT03042312)"],"prefix":"10.2967","volume":"62","author":[{"given":"Jeremie","family":"Calais","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Czernin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"Thin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeannine","family":"Gartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wesley R.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Allen-Auerbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Quon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shadfar","family":"Bahri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawan","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Gardner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"Dahlbom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beilei","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rouzbeh","family":"Esfandiari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ranganathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Eiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang P.","family":"Fendler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebrahim","family":"Delpassand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2021,7,16]]},"reference":[{"key":"2022032307250578000_62.10.1447.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607427"},{"key":"2022032307250578000_62.10.1447.2","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.10661"},{"key":"2022032307250578000_62.10.1447.3","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.114.147413"},{"key":"2022032307250578000_62.10.1447.4","doi-asserted-by":"crossref","unstructured":"Ahmadzadehfar H Eppard E K\u00fcrpig S . Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer. Oncotarget. 2016;7:12477.","DOI":"10.18632\/oncotarget.7245"},{"key":"2022032307250578000_62.10.1447.5","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.183194"},{"key":"2022032307250578000_62.10.1447.6","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.171397"},{"key":"2022032307250578000_62.10.1447.7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.11.076"},{"key":"2022032307250578000_62.10.1447.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1213755"},{"key":"2022032307250578000_62.10.1447.9","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-015-3125-3"},{"key":"2022032307250578000_62.10.1447.10","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-015-3174-7"},{"key":"2022032307250578000_62.10.1447.11","doi-asserted-by":"crossref","unstructured":"Calais J Gafita A Eiber MR . Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with 177Lu-PSMA-617 for metastatic Castration-reSISTant Prostate Cancer (RESIST-PC): Efficacy results of the UCLA cohort. J Nucl Med. May 20, 2021 [Epub ahead of print].","DOI":"10.2967\/jnumed.121.261982"},{"key":"2022032307250578000_62.10.1447.12","doi-asserted-by":"publisher","DOI":"10.1007\/s10278-004-1014-6"},{"key":"2022032307250578000_62.10.1447.13","doi-asserted-by":"publisher","DOI":"10.2310\/7200.2006.023"},{"key":"2022032307250578000_62.10.1447.14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.2702"},{"key":"2022032307250578000_62.10.1447.15","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1007\/s00259-020-04703-3","article-title":"Radioligand therapy using [177Lu]Lu-PSMA-617 in mCRPC: a pre-VISION single-center analysis","volume":"47","author":"Seifert","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2022032307250578000_62.10.1447.16","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1093\/ckj\/sfz101","article-title":"Renal outcomes of radioligand therapy: experience of 177lutetium\u2014prostate-specific membrane antigen ligand therapy in metastatic castrate-resistant prostate cancer","volume":"13","author":"Gallyamov","year":"2019","journal-title":"Clin Kidney J."},{"key":"2022032307250578000_62.10.1447.17","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.236414"},{"key":"2022032307250578000_62.10.1447.18","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet."},{"key":"2022032307250578000_62.10.1447.19","doi-asserted-by":"crossref","unstructured":"Sartor O de Bono J Chi KN . Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. June 2021:NEJMoa2107322.","DOI":"10.1056\/NEJMoa2107322"},{"key":"2022032307250578000_62.10.1447.20","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13550-018-0408-2","article-title":"Impact of external cooling with icepacks on 68Ga-PSMA uptake in salivary glands","volume":"8","author":"van Kalmthout","year":"2018","journal-title":"EJNMMI Res."},{"key":"2022032307250578000_62.10.1447.21","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.226449"},{"key":"2022032307250578000_62.10.1447.22","doi-asserted-by":"publisher","DOI":"10.1200\/JGO.17.00175"},{"key":"2022032307250578000_62.10.1447.23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040720"},{"key":"2022032307250578000_62.10.1447.24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911206"},{"key":"2022032307250578000_62.10.1447.25","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(91)90171-Y"},{"key":"2022032307250578000_62.10.1447.26","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2214\/AJR.18.20845","article-title":"Radioligand therapy with 177 Lu-PSMA for metastatic castration-resistant prostate cancer: a systematic review and meta-analysis","volume":"213","author":"Yadav","year":"2019","journal-title":"AJR."},{"key":"2022032307250578000_62.10.1447.27","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30198-0"},{"key":"2022032307250578000_62.10.1447.28","doi-asserted-by":"crossref","first-page":"v329","DOI":"10.1093\/annonc\/mdz248.006","article-title":"Preliminary results of a phase I\/II dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC)","volume":"30","author":"Tagawa","year":"2019","journal-title":"Ann Oncol."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.121.262543","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T14:26:19Z","timestamp":1648045579000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.121.262543"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,16]]},"references-count":28,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,10,1]]},"published-print":{"date-parts":[[2021,10]]}},"alternative-id":["10.2967\/jnumed.121.262543"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.121.262543","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,16]]}}}